Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

At Richmond, we are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth. As part of this commitment, we have taken an important step forward by participating in AstraZeneca’s Sustainability Accelerator Programme, designed to equip businesses within its global supply chain with practical strategies for sustainability.

Leading this initiative at Richmond is Elizabeth Romano, Director of Communications and Participant Engagement, who champions ESG across the organisation. As part of her role, Liz is driving the integration of sustainability into our business strategy, ensuring that environmental responsibility, ethical governance, and social impact remain at the forefront of our clinical research operations.

Advancing Sustainable Clinical Research

The clinical research industry plays a crucial role in the future of healthcare, and sustainability is now a key factor in long-term success. Richmond is committed to:

✅ Reducing environmental impact by adopting sustainable operational practices.
✅ Enhancing social responsibility through patient-centred research and ethical governance.
✅ Aligning with global ESG frameworks to drive efficiency and responsible business practices.

By participating in initiatives like the Sustainability Accelerator Programme, Richmond Pharmacology is reinforcing its role as a forward-thinking, responsible clinical research organisation. As sustainability continues to shape the future of clinical trials, we remain dedicated to implementing best practices that benefit both our industry and the wider global community.

Stay tuned for more updates as we continue to evolve our sustainability strategy or to find out more read here.